Plus, news about Applied Therapeutics, Beam Therapeutics, Janux Therapeutics and more:
Viking Therapeutics sells off $350M of stock following positive obesity drug data: On the same day that Viking shared positive topline data for its “double G” GLP-1/GIP receptor agonist that could compete with Eli Lilly’s Zepbound, the company announced a public offering, aiming to sell $350 million of its shares. Viking said it would use the money to develop its obesity drug as well as others in its pipeline. — Katherine Lewin
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.